key: cord-0931995-cj10d6ip
authors: Kantauskaite, Marta; Müller, Lisa; Kolb, Thilo; Fischer, Svenja; Hillebrandt, Jonas; Ivens, Katrin; Andree, Marcel; Luedde, Tom; Orth, Hans M.; Adams, Ortwin; Schaal, Heiner; Schmidt, Claudia; Königshausen, Eva; Rump, Lars C.; Timm, Jörg; Stegbauer, Johannes
title: Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS‐CoV‐2 vaccination in kidney transplant recipients
date: 2021-11-01
journal: Am J Transplant
DOI: 10.1111/ajt.16851
sha: 666388767ed4b27cab379edabe59c570873f143a
doc_id: 931995
cord_uid: cj10d6ip

Kidney transplant recipients (KTRs) are extremely vulnerable to SARS‐CoV‐2 infection and show an impaired immune response to SARS‐CoV‐2 vaccination. We analyzed factors related to vaccination efficiency in KTRs. In a multicenter prospective observational study (NCT04743947), IgG antibodies levels against SARS‐CoV‐2 spike S1 subunit and their neutralization capacity after SARS‐CoV‐2 vaccination were analyzed in 225 KTRs and compared to 176 controls. After the vaccination, 56 (24.9%) KTRs became seropositive of whom 68% had neutralizing antibodies. This immune response was significantly lower compared to controls (239 [78–519] BAU/ml versus 1826 [560–3180] BAU/ml for KTRs and controls, p < .0001). The strongest predictor for an impaired response was mycophenolate mofetil (MMF) treatment. Multivariate regression analysis revealed that MMF‐free regimen was highly associated with seroconversion (OR 13.25, 95% CI 3.22–54.6; p < .001). In contrast, other immunosuppressive drugs had no significant influence. 187 out of 225 KTRs were treated with MMF of whom 26 (13.9%) developed antibodies. 23 of these seropositive KTRs had a daily MMF dose ≤1 g. Furthermore, higher trough MMF concentrations correlated with lower antibody titers (R −0.354, p < .001) supporting a dose‐dependent unfavorable effect of MMF. Our data indicate that MMF dose modification could lead to an improved immune response.

In comparison to the general population, kidney transplant recipients (KTRs) have a significantly higher risk of severe, lifethreatening acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. 1 Currently, vaccination against SARS-CoV-2 appears to be the best prophylaxis against the severe course of COVID-19 infection. Unfortunately, recent observational studies suggest, that the majority of KTRs do not develop sufficient antibody levels after SARS-CoV-2 vaccination. [2] [3] [4] [5] Moreover, the occurrence of COVID-19 infection among vaccinated KTRs is almost always related to seronegative status. 6, 7 Based on these disappointing data, it is essential to identify factors influencing the immune response in KTRs. The overall goal is to develop new SARS-CoV-2 vaccination strategies which increase the probability for a positive immune response.

During this prospective multicenter observational study, the humoral immune response to SARS-CoV-2 vaccination (either BNT162b2; Biontech/Pfizer or mRNA-1273; Moderna) was measured in 225 KTRs (NCT04743947) and compared to 176 volunteers (controls). Shortly, the previously described control group was composed of volunteers from a nursing home, who had no history of kidney failure. 8 Twenty-eight of the 225 KTRs were included in a previously published study. 9 All participants had to be older than 18 years, with no history of previous COVID-19 and able to give informed consent to participate in the study. All KTRs were on stable immunosuppressive medication. None of the KTRs had an acute graft rejection. Eight KTRs were treated for a rejection in the last 12 months. Mentioned vaccines were administered as advised by the manufacturer. The study was approved by the ethics committee of the Medical Faculty at the Heinrich-Heine University, Düsseldorf, Germany (study numbers 2020-1237 and 2021-1287, respectively) and in line with the Declaration of Helsinki, as revised in 2013.

Immune response to SARS-CoV-2 vaccination was measured at mean 14 ± 2 days and 17 days post vaccination in KTRs and control group respectively. All samples were tested for IgG antibodies against SARS-CoV-2 spike S1 subunit using Anti-SARS-CoV-2-QuantiVac-ELISA (Euroimmun AG) as well as for SARS-CoV-2 neutralization efficacy (NT) at the Institute of Virology, University Hospital Düsseldorf, Germany. According to the manufacturer's instruction results <25.6 BAU/ml were considered as negative, ≥25.6 BAU/ml and ≤35.2 BAU/ml as indeterminate, and >35.2 BAU/ ml as positive (BAU, Binding Antibody Units). The upper detection limit for undiluted samples was >384 BAU/ml, the lower detection limit was <3.2 BAU/ml. For samples above the detection limit, 1:10 or 1:100 dilutions were performed in IgG sample buffer according to the manufacturer's instructions.

To detect the neutralizing capacity of the Anti-SARS-CoV-2 antibodies after the second vaccination, an endpoint dilution neutralization test with the infectious SARS-CoV-2 B.1 isolate (EPI_ ISL_425126) at a TCID 50 of 100 was performed in a BSL-3 facility as described previously. 10 At the time of this study, no other variants were established in the lab for the neutralization test. The neutralization titer was determined as the highest serum dilution without virus-induced cytopathic effect (CPE).

Statistical analysis was performed using SPSS version 23 (SPSS Inc.) and Graph Prism 5.3 (GraphPad Software). Data distribution was evaluated using Shapiro-Wilk normality test and expressed as mean ± standard deviation (SD) or median (interquartile ranges expressed as two numbers, Q1-Q3, respectively). Categorical variables are expressed as number (percentage). The difference among immune response groups was evaluated using the Chi-square test or Mann-Whitney test where appropriate. Multivariate logistic regression was used for indicating variables associated with a positive immune response after SARS-CoV-2 vaccination. p values less than 0.05 were considered statistically significant.

Characteristics of the KTR population are presented in Table 1 . KTRs in the seropositive group defined as anti-SARS-CoV-2 spike S1 antibody levels >35.2 BAU/ml compared to seronegative patients, had lower rates of triple immunosuppressive therapy and less use of MMF accompanied by significantly longer time after transplantation (Table 1 ). Other immunosuppressive agents as well as differences in age, gender and graft function had no influence on the immune response (Table 1) . Seropositive patients with neutralizing antibodies (n = 38) compared to seropositive patients without neutralizing antibodies (n = 18) did not differ with respect to immunosuppression, graft function or time after transplantation (Table 2) . KTRs with higher IgG antibody levels were more likely to develop neutralizing antibodies with higher titers ( Figure 1C ; Table 2) .

To evaluate independent factors which modify the immune response in KTRs, logistic multivariate regression analysis was performed (Table 3) . By adjusting to age, gender, graft function and immunosuppressive agents, a MMF-free regimen (OR 13.25, 95% CI 3.22-54.6; p < .001) and degree of graft function (OR 1.03, 95% CI 

In this study, a very low humoral immune response to SARS-CoV-2 vaccine in KTRs compared to controls with no history of kidney failure was demonstrated. This is in accordance with other recent studies. [2] [3] [4] [5] Importantly, KTRs have significantly lower neutralizing capacity against SARS-CoV-2 as compared to controls suggesting a severely impaired sero-protection. Only 68% of seropositive patients showed neutralizing antibodies. Smaller cohorts representing KTRs failed to demonstrate any neutralizing antibody capacity in these patients. 11, 12 In fact, the presence and in particular the titer levels of the neutralizing antibodies correlate with efficient protection influencing the immune response after SARS-CoV-2 vaccination in KTRs. 4, 15 These associations could not be found in our study as the patient number taking these immunosuppression drugs was too low.

Recent observational case series report, that a third vaccination against SARS-CoV-2 improves the immune response especially in those KTRs with detectable but low antibody titers. However, approximately half of the KTRs remained seronegative even after the third vaccination. 20, 21 A limitation of this study is that we did not measure T cell re- and HMO contributed to investigation. MK contributed to writingoriginal draft preparation. TK, TL, HMO, LCR, JT, and JS contributed to review and editing. JT and JS contributed to supervision.

Raw data were generated at University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany. The data that support the findings of this study are available on request from the corresponding author, JS. The data are not publicly available due to privacy restrictions.

Johannes Stegbauer https://orcid.org/0000-0001-8994-8102

COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients

Impaired humoral response in renal transplant recipients to sars-cov-2 vaccination with bnt162b2 (Pfizer-biontech)

Occurrence of severe COVID-19 in vaccinated transplant patients

Clinically significant COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients

Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination

Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients

Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting

Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients

Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study

Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients

Suppression of the humoral immune response by mycophenolate mofetil

Low response to HBsAg vaccine in chronic renal failure patients is not due to intrinsic defect of B cells

Uremia-associated immunological aging and severity of COVID-19 infection

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

Safety and Immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection